Safety and Cost-effectiveness of Paclitaxel Administered as a 1-Hour Infusion Versus a 3-Hour Infusion for Various Malignancies

    loading  Checking for direct PDF access through Ovid

Abstract

This study challenges the current practice of administering paclitaxel for a variety of malignancies over 3 hours and documents the safety and cost-effectiveness of 1-hour administration in the outpatient setting. The authors investigated opportunities to save nursing time and costs in a cancer clinic without compromising patient safety. These savings are referred to as “opportunity-cost savings” that enable the clinic to schedule more patients during the time normally required to administer a 3-hour paclitaxel dose. Over a 2-year period, the authors were able to document significant time savings with no increase in adverse drug reactions.

Related Topics

    loading  Loading Related Articles